seri
novel
acycl
nucleosid
phosphon
anp
variou
nucleobas
ethyl
pee
chain
bear
variou
substitu
bposit
phosphon
moieti
prepar
influenc
structur
altern
antivir
activ
studi
sever
deriv
exhibit
antivir
activ
hiv
vaccinia
viru
middl
micromolar
rang
lower
micromolar
rang
vzv
cmv
nanomolar
rang
although
parent
unbranch
peeanp
inact
adenin
nucleobas
methyl
group
attach
pee
chain
prove
prerequisit
afford
pronounc
antivir
activ
acycl
nucleosid
phosphon
anp
possess
signific
antivir
cytostat
activ
nucleotid
analog
contain
isopolar
phosphonomethyl
moieti
instead
nucleotid
phosphat
ester
group
exclud
enzymat
degrad
andor
elimin
problem
link
intracellular
phosphoryl
necessari
nucleosid
activ
excel
templat
drug
design
absenc
labil
glycosid
bond
flexibl
acycl
chain
enabl
compound
adopt
suitabl
conform
target
enzym
among
anp
phosphonomethoxi
alkyl
deriv
purin
pyrimidin
base
particularli
potent
ethyl
adenin
pmea
fig
activ
dna
virus
retrovirus
prodrug
adefovir
dipivoxil
approv
hepat
b
viru
therapi
attach
hydroxymethyl
group
phosphonomethoxi
ethyl
chain
lead
anoth
activ
compound
phosphonomethoxi
propyl
adenin
hpmpa
fig
potent
antidnavir
activ
substitut
aliphat
pmea
side
chain
methyl
group
result
r
phosphonomethoxi
propyl
adenin
pmpa
fig
high
potenc
select
oral
prodrug
tenofovir
disoproxil
fumar
approv
treatment
hiv
infect
recent
also
hbv
infect
structureact
relationship
studi
seri
pmea
congen
includ
modif
parent
molecul
side
chain
eg
unsatur
aryl
anp
heterocycl
moieti
demonstr
margin
structur
alter
narrow
except
antivir
activ
cytosin
deriv
hpmpc
choic
base
limit
mostli
adenin
guanin
congen
specif
antivir
action
predominantli
determin
structur
side
chain
anp
chain
elong
ch
group
phosphonoethoxi
ethyl
pee
compound
exhibit
signific
antivir
activ
deriv
peeg
peehx
fig
key
enzym
purin
salvag
pathway
essenti
replic
surviv
parasit
plasmodium
falciparum
k
valu
peeg
peehx
lm
respect
investig
effect
branch
phosphonoethoxyethyl
chain
select
abil
inhibit
pfhgxprt
human
hgprt
substitu
ad
either
carbon
attach
directli
phosphoru
atom
abranch
deriv
adjac
carbon
bbranch
deriv
abranch
weak
inhibitor
bbranch
compound
bind
tightli
enzym
herein
report
synthesi
antivir
activ
seri
anp
bbranch
pee
moieti
investig
structureact
relationship
group
compound
influenc
nucleobas
variou
substitu
peechain
studi
prepar
anp
divid
three
group
deriv
adenin
base
variant
bsubstitu
b
deriv
ethyl
chain
variou
purin
pyrimidin
base
analog
pmpcompound
c
deriv
benzylprotect
congen
variou
nucleobas
ethyl
chain
analog
structur
motif
deriv
hpmpanp
previous
publish
synthes
branch
phosphon
suffer
mainli
elimin
reaction
extens
seri
bbranch
peeanp
decid
improv
previous
publish
method
prepar
diethyl
alkylphosphon
procedur
significantli
simplifi
provid
conveni
rapid
access
broad
spectrum
phosphon
deriv
main
improv
compar
previous
publish
stepvis
procedur
onepot
sequenc
without
isol
branch
alcohol
first
step
start
commerci
avail
diethyl
methylphosphon
scheme
diethyl
lithiomethylphosphon
preform
situ
dri
thf
argon
atmospher
react
correspond
aldehyd
result
intermedi
directli
alkyl
ethyl
bromoacet
mild
condit
avoid
elimin
reaction
ethyl
alkoxi
acet
moieti
compound
serv
latent
hydroxyethyl
group
ester
reduc
boran
thf
obtain
desir
hydroxi
deriv
alreadi
builtin
ether
bond
overal
yield
three
step
sequenc
result
alcohol
introduc
mitsunobu
condit
purin
pyrimidin
base
scheme
thu
alkyl
alcohol
form
anp
diethyl
ester
respect
detail
synthesi
given
previou
paper
procedur
follow
basedeprotect
use
alkyl
form
pyrimidin
deriv
respect
expect
previou
experi
yield
mitsunobu
reaction
moder
procedur
purin
seri
scheme
base
modif
heterocycl
moieti
follow
cleavag
ester
group
standard
condit
sibracetonitril
hydrolysi
thu
heat
deriv
methanol
ammonia
autoclav
afford
intermedi
subsequ
cleavag
ethyl
group
adenin
bbranch
peecompound
obtain
reaction
benzyl
group
partial
cleav
addit
hydroxi
deriv
isol
second
product
routin
procedur
appli
hydrolyz
halogen
purin
deriv
obtain
hypoxanthin
guanin
anp
reaction
aqueou
trifluoroacet
acid
gave
compound
respect
suffici
amount
product
debenzyl
hydrogenolysi
pdc
form
hydroxymethyl
peederiv
final
diethyl
ester
e
e
transform
target
free
phosphon
acid
e
e
procedur
mention
adenin
anp
appli
synthesi
diaminopurin
compound
case
start
deriv
pph
diadthf
pph
diadthf
thymin
uracil
scheme
pyrimidin
seri
scheme
benzyl
deriv
prepar
mitsunobu
approach
debenzyl
hydrogenolysi
pdc
form
hydroxymethyl
compound
respect
uracil
methylpe
diester
convert
cytosin
deriv
treatment
chlorid
follow
amin
ammonium
hydroxid
diethyl
ester
deriv
cytosin
thymin
e
uracil
e
treat
bromotrimethylsilan
subsequ
hydrolysi
free
phosphon
acid
e
e
isol
respect
entitl
novel
bbranch
phosphonoethoxyethyl
anp
e
e
e
e
well
previous
publish
guanin
hypoxanthin
deriv
evalu
variou
dna
virus
includ
poxvirus
ie
vaccinia
viru
vacv
herpesvirus
ie
herp
simplex
viru
type
type
thymidin
kinasedefici
acyclovirresist
acv
r
varicellazost
viru
vzv
human
cytomegaloviru
hcmv
tabl
compound
also
evalu
retrovirus
ie
human
immunodefici
viru
type
type
compound
also
examin
sever
rna
virus
includ
vesicular
stomat
viru
vsv
coxsacki
viru
respiratori
syncyti
viru
rsv
parainfluenza
viru
type
sindbi
viru
punta
toro
viru
none
compound
show
activ
differ
rna
virus
except
compound
e
prove
inact
herpesand
poxvirus
compound
contrast
parent
unbranch
peeanp
exhibit
least
moder
antiherp
antipoxviru
activ
summar
tabl
valu
lm
henc
select
indic
ratio
cc
ec
compound
differ
vzv
strain
hcmv
hsv
vaccinia
viru
compar
respect
cidofovir
replac
group
et
ch
ph
group
result
decreas
cytostat
activ
cc
valu
respect
lm
also
diminish
antivir
activ
herpesand
poxvirus
benzylsubstitut
deriv
show
antivir
activ
methyl
activ
ethyl
least
activ
deriv
also
replac
methyl
hydroxymethyl
annihil
antidna
viru
activ
substitut
adenin
nucleobas
uracil
thymin
cytosin
result
lower
cystostat
effect
also
virtual
complet
loss
antivir
potenc
among
differ
bbranch
phosphonoethoxyethyl
anp
abl
inhibit
replic
ec
lm
ec
lm
cem
cell
cultur
antiretrovir
activ
concentr
rang
pmea
adefovir
ec
lm
lm
howev
cystostat
activ
cem
cell
cc
lm
may
account
antihiv
activ
observ
thu
observ
antihiv
activ
might
due
direct
inhibit
viru
replic
rather
indirect
cellular
antimetabol
activ
compound
also
demonstr
higher
cystostat
activ
cell
cultur
compar
compound
observ
cytostat
activ
human
fibroblast
hel
cell
prolifer
evalu
murin
leukemia
cell
murin
mammari
carcinoma
cell
human
tlymphocyt
cell
cem
far
cytostat
tabl
methodolog
synthesi
bbranch
acycl
nucleosid
phosphon
pee
moieti
significantli
improv
seri
new
purin
pyrimidin
deriv
synthes
although
parent
unsubstitut
peeanp
antivir
inact
attach
methyl
ethyl
benzyl
substitu
acycl
aliphat
chain
lead
antivir
activ
compound
especi
adenin
seri
new
result
contribut
extens
sar
project
aim
develop
new
select
antivir
drug
unless
otherwis
state
solvent
evapor
kpa
compound
dri
p
kpa
nmr
spectra
record
bruker
avanc
h
mhz
c
mhz
spectromet
tm
intern
standard
referenc
residu
solvent
signal
mass
spectra
measur
zabeq
vg
analyt
spectromet
chemic
obtain
commerci
sourc
sigmaaldrich
prepar
accord
publish
procedur
dimethylformamid
acetonitril
distil
p
store
molecular
siev
thf
distil
sodium
benzophenon
ketyl
argon
deionis
perform
dowex
h
form
column
follow
procedur
applic
crude
product
column
wash
water
uv
absorpt
drop
thereaft
column
elut
aqueou
nh
chromatographi
dowex
acet
form
follow
applic
aqueou
solut
crude
product
onto
column
wash
water
uv
absorpt
drop
column
elut
gradient
dilut
acet
formic
acid
test
anp
character
h
nmr
c
nmr
mass
spectrometri
puriti
target
compound
determin
combust
element
analysi
c
h
n
solut
nbutyllithium
hexan
ml
ad
slowli
stir
solut
diethyl
methanephosphon
g
mmol
dri
thf
ml
cool
argon
atmospher
min
vigor
stir
benzyloxyacetaldehyd
g
mmol
ad
reaction
mixtur
allow
rise
stir
h
ethyl
bromoacet
ml
mmol
ad
temperatur
reaction
mixtur
allow
rise
slowli
room
temperatur
overnight
stir
diethyl
ether
ml
ad
mixtur
wash
satur
nacl
solut
organ
layer
dri
anhydr
magnesium
sulfat
solvent
evapor
crude
intermedi
ethyl
benzyloxi
diethoxyphosphoryl
acet
purifi
chromatographi
silica
gel
hexanechcl
meoh
use
follow
step
intermedi
cool
solut
boran
thf
ml
ad
argon
atmospher
reaction
mixtur
stir
room
temperatur
day
methanol
ml
ad
solut
concentr
evolut
hydrogen
stop
residu
purifi
chromatographi
silica
gel
hexanechcl
meoh
product
g
obtain
yield
three
step
solut
triphenylphosphin
g
mmol
dri
thf
ml
cool
argon
atmospher
diisopropylazadicarboxyl
diad
ml
mmol
ad
slowli
mixtur
stir
min
preform
complex
ad
reaction
mixtur
contain
correspond
heterocycl
base
mmol
dri
thf
ml
diethyl
phosphon
mmol
argon
result
mixtur
slowli
warm
room
temperatur
stir
h
procedur
differ
correspond
deriv
solvent
evapor
crude
mixtur
purifi
chromatographi
silica
gel
meohchcl
yield
start
water
ml
ad
reaction
mixtur
heat
h
diethyl
ether
ml
ad
mixtur
wash
satur
nacl
solut
organ
layer
dri
anhydr
magnesium
sulfat
solvent
evapor
pure
product
obtain
chromatographi
silica
gel
chloroformmeoh
yield
start
h
nmr
dmsod
solvent
evapor
methanol
ml
naom
methanol
ml
ad
solut
stir
overnight
neutral
aqueou
hcl
solvent
evapor
crude
mixtur
purifi
chromatographi
silica
gel
chloroformmeoh
yield
start
procedur
thymin
deriv
appli
yield
start
procedur
thymin
deriv
appli
yield
start
solut
deriv
mmol
methanol
ammonia
ml
stir
autoclav
h
solvent
evapor
residu
codistil
acetonitril
mixtur
crude
diethyl
ester
adenin
intermedi
acetonitril
ml
brsime
ml
stir
overnight
room
temperatur
evapor
codistil
acetonitril
residu
treat
aqueou
ammonia
evapor
dryness
residu
appli
onto
column
dowex
h
form
ml
wash
water
elut
aqueou
ammonia
evapor
afford
crude
product
ammonium
salt
residu
appli
onto
column
dowex
acet
ml
wash
water
follow
gradient
acet
acid
formic
acid
main
uvabsorb
fraction
evapor
codistil
water
obtain
product
white
solid
start
deriv
yield
two
step
h
nmr
dmsod
br
nh
j
dt
j
j
g
dt
j
j
g
h
n
found
c
h
n
h
n
found
c
h
n
n
found
c
h
n
j
dd
j
j
g
dd
j
j
g
dd
j
j
g
b
start
deriv
procedur
use
yield
two
step
transform
deriv
hypoxanthin
guanin
deriv
gener
procedur
deriv
mmol
dissolv
trifluoroacet
acid
ml
stir
overnight
solvent
evapor
residu
codistil
water
ethanol
crude
mixtur
purifi
chromatographi
silica
gel
chloroformmeoh
compound
mg
mmol
et
n
ml
chlorid
g
mmol
stir
ch
cn
ml
room
temp
day
nh
oh
ml
ad
mixtur
stir
h
solvent
evapor
residu
ethyl
acet
wash
brine
aqueou
fraction
wash
five
portion
chcl
organ
fraction
dri
mgso
concentr
reduc
pressur
crude
product
purifi
flash
chromatographi
give
mg
synthesi
phosphon
acid
e
e
e
e
gener
procedur
mixtur
diethyl
ester
mmol
acetonitril
ml
brsime
ml
stir
overnight
room
temperatur
evapor
codistil
acetonitril
residu
treat
aqueou
ammonia
evapor
dryness
residu
appli
onto
column
dowex
acet
ml
wash
water
follow
gradient
acet
acid
formic
acid
main
uvabsorb
fraction
evapor
codistil
water
obtain
product
white
solid
ethyl
hypoxanthin
cytostat
activ
measur
base
inhibit
cell
growth
hel
cell
seed
rate
cellswel
microtit
plate
allow
prolifer
h
medium
contain
differ
concentr
test
compound
ad
day
incub
cell
number
determin
coulter
counter
cytostat
concentr
calcul
cc
compound
concentr
requir
reduc
cell
prolifer
rel
number
cell
untreat
control
cc
valu
estim
graphic
plot
number
cell
percentag
control
function
concentr
test
compound
altern
cytotox
test
compound
express
minimum
cytotox
concentr
mcc
compound
concentr
caus
microscop
detect
alter
hel
cell
morpholog
cytostat
activ
murin
leukemia
murin
mammari
carcinoma
cem
human
tlymphoblast
cell
line
measur
essenti
origin
describ
mous
leukemia
cell
assay
